Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

70% Of Brits Do Not Practice 'Safe Sun'
With the heat wave hitting all corners of the UK this week, millions of adults will be flocking to the seaside in search of sun, sea, sand and a much needed snooze. Unfortunately many are likely to end up needing medical treatment for severe burning, prickly heat or heatstroke. As seven out of ten Brits will not be practicing "safe sun" and will foolhardily be going without wearing any sun cream.

Better Outcomes With Computer Aided Surgery - High Costs As An Obstacle To Broad Use
There are many indications that computer aided surgery has a major role to play in improving results in orthopaedic surgery, says Dr. Stefano Zaffagnini, who has played a pioneering role in the use of this technology and who moderates a symposium on this theme at the Congress of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT), taking place from June 3 to 6 in Vienna, with more than 8,000 participants from around the world. This technology should allow total knee prosthesis using minimally invasive surgery to become a standard procedure within a decade. Osteotomy and hip operations are only two of the many other fields where computer aided surgery can also markedly improve results for patients, experts state at the EFFORT Congress in Vienna.
News of the day
Evaluating Language In Children With Autism
A new parent questionnaire, developed at the University of Waterloo, will help health practitioners to more accurately gauge the acquisition of language skills in children with autism.
Mental Health

Biovista Inc. Announces Positive Efficacy Results In A Pre-Clinical Trial Of Its BVA-601 Repositioned Drug For Epilepsy

Biovista Inc. announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant decrease of epileptic activity in mice pre-treated with Kainic acid. "We are pleased with these initial results that confirm the predicted efficacy of BVA-601 and encourage us to further test and develop this compound in a disease area where there is a need for new, patient-friendly therapies," said Aris Persidis, Ph.D., President of Biovista. "This successful repositioning builds on our previously reported success with BVA-101 in multiple sclerosis, expanding our CNS portfolio. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company," added Dr. Persidis. Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures may be transient signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain. Epilepsy is one of the world"s oldest recognized conditions, affecting around 50 million people worldwide. Fear, discrimination and social stigma have surrounded epilepsy for centuries. Some of the stigma continues today in many countries impacting the quality of life of people with the disorder. In the animal proof of concept trial, BVA-601 was compared to diazepam, a potent anti-epileptic drug that is efficient in reducing epileptic activity but has troubling adverse events. BVA-601 induced a statistically significant reduction in the number of animals showing epileptic activity and delayed the onset of epileptic seizures. About Biovista"s repositioning pipeline and technology platform Biovista applies high-efficiency discovery efforts to finding solutions for commercially relevant unmet medical needs. Biovista"s proprietary repositioning technology allows it to perform mechanism-of-action based analyses and systematically assess clinical outcomes in any therapeutic area of interest, at relatively low cost and short time spans. The company is presently using this platform to develop its own pipeline of repositioned drugs in areas such as CNS, cardiovascular disease, oncology and autoimmune diseases. Biovista Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009